Evidence map›Paper›PMID 8738610›Full record

ArticleBreast cancer research and treatment1996

Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis.

S W McLeskey, L Zhang, S Kharbanda, J Kurebayashi, M E Lippman, R B Dickson, F G Kern

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Hypoxia reduces hormone responsiveness of human breast cancer cells.Japanese journal of cancer research : Gann · 2001
    Article
  5. Article
  6. The role of stroma in breast carcinoma growth in vivo.Journal of mammary gland biology and neoplasia · 1998
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

S W McLeskeyLombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC 20007, USA.
L Zhang
S Kharbanda
J Kurebayashi
M E Lippman
R B Dickson
F G Kern
Georgetown University Medical Center · USGeorgetown University · USCancer Research Center · US

Funding

SPORE IN BREAST CANCERP50CA058185 · NCI · GEORGETOWN UNIVERSITY · PI DICKSON, ROBERT B. · 1992 to 2004
$4.0M
GENETIC MECHANISMS OF BREAST TUMOR PROGRESSIONR01CA050376 · NCI · SOUTHERN RESEARCH INSTITUTE · PI KERN, FRANCIS G. · 1989 to 2004
$2.3M
SIGNAL TRANSDUCTIONU01CA051908 · NCI · GEORGETOWN UNIVERSITY · PI MARTIN, MARY BETH · 1990 to 1994
–
NCI NIH HHS CA50376NCI NIH HHS CA51908NCI NIH HHS CA58185
6 · The paper itself

Abstract

Progression of breast cancer from an estrogen-dependent, slowly growing tumor amenable to tamoxifen treatment to an aggressive, metastatic, estrogen-independent phenotype has been mimicked by the transfection of MCF-7 breast carcinoma cells with fibroblast growth factors 1 or 4. FGF-transfected cells are aggressively tumorigenic in ovariectomized or tamoxifen-treated nude mice, conditions under which the parental cells would not produce tumors. When detection of metastasis was enhanced by lacZ transfection, the FGF-transfected MCF-7 cells were reliably metastatic to lymph nodes and frequently metastatic to lungs, in further contrast to parental cells. An antiangiogenic drug, AGM-1470, given to mice bearing tumors produced by FGF-transfected MCF-7 cells, produced a decrease in tumor size. The decreased tumor size was not as marked as that produced by treatment with pentosan polysulfate, an agent which would abrogate all autocrine or paracrine effects of the transfected FGF. Thus, increased angiogenesis may be a component of the phenotypic change produced by the FGF transfection, but other autocrine or paracrine effects may also be important. Since a clonal FGF-4 and lacZ doubly-transfected cell line, MKL-4, progressively lost expression of the transfected lacZ gene in individual cells, we performed successive rounds of fluorescence-activated cell sorting to select high-expressing cells. High-expressing cell populations thus obtained rapidly lost expression of beta-gal activity in continued culture. High beta-gal expressing clonal cell lines of MKL-4 cells established by either one or two rounds of low-density cloning also lost lacZ expression with continued culture. Southern analysis of DNA from lacZ transfected cell lines showed the transfected sequences to be present and grossly intact in both high and low expressing populations. However, Northern analysis revealed that high-expressing populations of MKL-4 cells contained the most lacZ mRNA, implying that in the unstable MKL-4 cell line, individual cells are down-regulating mRNA levels of lacZ. Stable lacZ expression has been obtained in other FGF-transfected and parental MCF-7 cell lines using the same expression vector. Thus, the MKL-4 cell line is down-regulating mRNA encoding the transfected gene through a mechanism not dependent on the CMV promotor utilized in the expression vector. This evidence suggests that lacZ expression is not a benign modification in certain cells.

Indexed as

Disease Models, AnimalAnimalsBreast NeoplasmsCarcinomaCell DivisionFemaleFibroblast Growth FactorsGene Expression Regulation, NeoplasticHumansLac OperonMiceMice, NudeNeoplasm MetastasisNeovascularization, PathologicReceptors, Fibroblast Growth FactorTransfectionFibroblast Growth FactorsReceptors, Fibroblast Growth Factor

Identifiers

PMID8738610
OpenAlexW2067445798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.